Wolfgang Miesbach: What the Latest Gene Therapy Setbacks Mean for Haemophilia Care
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Another setback — and what it means.
Be Biopharma has terminated its Phase 1/2 BeCoMe-9 trial of BE-101, an autologous B-cell therapy for severe haemophilia B, after enrolling just 5 of 24 planned patients – a ‘strategic business decision’ not a safety issue.
BE-101 edited patients’ own B cells ex vivo to produce FIX, with stable activity and re-dosing potential.
It was one of the very few B-cell therapies so far.
This comes on top of:
- Pfizer cutting all funding and global rollout of its approved haemophilia B gene therapy Beqvez, citing limited interest from patients and physicians
- BioMarin withdrawing its haemophilia A gene therapy Roctavian after slow uptake and modest sales, despite regulatory success
So what does this mean for gene therapy in haemophilia?
Approval and elegant biology are not equivalent to real-world adoption.
Durability, re-dosing, eligibility, cost and system readiness are what decide.
Today’s ‘one-and-done’ liver-directed AAV approaches may stay niche while highly effective factor and non-factor prophylaxis remain widely available.
In my view, this is less a verdict against gene therapy than a call to align the next generation of trials and products with what truly matters to people with hemophilia: durable bleed protection, full reimbursement, and sustainable integration into care.”
Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering